TBCA

• Description :

  TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Casein Kinase

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/tbca.html

• Concentration :

  10mM

• Purity :

  99.45

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  OC(/C=C/C1=C(C(Br)=C(Br)C(Br)=C1)Br)=O

• Molecular Formula :

  C9H4Br4O2

• Molecular Weight :

  463.74

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Pagano MA, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007;8 (1) :129-139.|[2]Ryu SY, Kim S. Evaluation of CK2 inhibitor (E) -3- (2,3,4,5-tetrabromophenyl) acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013;720 (1-3) :391-400.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CK2

• CAS Number :

  [934358-00-6]